TheTechno Optimist.

Generate Biomedicines—Generate Biomedicines begins trading on Nasdaq after a $400M IPOGB-0895 (anti-TSLP)Generate Biomedicines—First patient dosed in Phase 3 SOLAIRIA program of GB-0895 in severe asthma

Generate Biomedicines

AI-designed proteins, antibodies

USpublicest. 2018generatebiomedicines.com (opens generatebiomedicines.com)Checked 25 Sep

The brief

Analyst view

IPO on 27 Feb 2026 raised $400M at $16 per share.
GB-0895 was built to last longer in the body, aiming for a shot every six months instead of monthly.

Programs

Generate Biomedicines, one program

Updated 1 Jan 2026

GB-0895 (anti-TSLP)An antibody that blocks TSLP, an early trigger of airway inflammation, tuned with AI to be strong and last a long time in the body.DeployNextPhase 3 fully enrolled (~1,600 patients) · 2028Updated 1 Jan 2026View program →

Research · Proto · Pilot · Deploy · Scaling

Research & demos

1 item

Nov 2023
paperIlluminating protein space with a programmable generative model (Nature) (opens doi.org)
Introduced Chroma, an AI that designs proteins with chosen properties.

Peers

AI drug discovery · 3

Company & funding

Listed: GENB (opens google.com)NASDAQ
HQ: US
Founded: 2018
Website: generatebiomedicines.com (opens generatebiomedicines.com)

Partners & customers

1 investor · 2 partners

Investor
Flagship Pioneering (opens flagshippioneering.com)
Founded and incubated the company.
Partner
Amgen (opens amgen.com)
Multi-target protein design collaboration from 2022.
Partner
Novartis (opens novartis.com)
Protein therapeutic collaboration from 2024.

People

Key people

Mike Nally (opens generatebiomedicines.com)CEO